Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients

  • Teva Pharmaceutical Industries Ltd (NYSE:TEVAannounced new study findings based on newly established clinical thresholds on short-acting beta-agonist (SABA) use and real-world usage of ProAir Digihaler (albuterol sulfate) inhalation powder.
  • ProAir Digihaler is a breath-actuated, digital SABA inhaler with built-in flow sensors that detect, record, and store objective data. 
  • 89% (319/359) of patients met the consensus threshold of SABA reliever medication use, and 72% (260/359) met the threshold of SABA reliever medication use ≥200% above baseline. 
  • Also Read: BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal.
  • 17% (62/359) of patients made 25 or more valid inhalations in a week, a level associated with unanimous consensus of likely impending or ongoing exacerbation.
  • 29% (104/359) of the patients exhibited a rate of SABA reliever use over 12 weeks, equivalent to three or more canisters per year.
  • Concurrently, Teva received the U.K. approval for Ongavia, a biosimilar to Lucentis (ranibizumab ), an eye injection, for neovascular (wet) age-related macular degeneration.
  • Lucentis is marketed by Genentech, a unit of Roche Holdings AG (OTC:RHHBY).
  • Price Action: TEVA shares are up 6.51% at $8.43 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.